Organization
Concert Pharmaceuticals, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Concert Pharmaceuticals, Inc.
... LEXINGTON, Mass. - Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2017. ...
... Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2017. ...
... LEXINGTON, Mass. - Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2017 ...
... Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed enrollment of the ...
... Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2017 ...
... to its Board of Directors. Dr. Tung is the scientific co-founder of Concert Pharmaceuticals, where he serves as President and Chief Executive Officer. Prior to ...
... of VX-561 (previously known as CTP-656), an investigational once-daily CFTR potentiator, from Concert Pharmaceuticals. Non-GAAP R&D expenses were $243.2 million compared to $211.0 million for ...
... LEXINGTON, Mass. - Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trials and Appeal Board (PTAB) ...
... Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trials and Appeal Board (PTAB) ...
... Concert Pharmaceuticals, Inc . (NASDAQ: CNCE) today announced that it will present a corporate overview ...
... LEXINGTON, Mass - Concert Pharmaceuticals Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of ...
... Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2017. ...
... Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2017 ...
... people with CF, including the completion of an asset purchase agreement with Concert Pharmaceuticals for worldwide development and commercialization rights to CTP-656 and other assets ...
... Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the U.S. Federal Trade Commission ("FTC") has ...
... GmbH, Catabasis Pharmaceuticals Inc, Celtaxsys Inc, Chiesi Farmaceutici SpA, Cilian AG, Concert Pharmaceuticals Inc, CRISPR Therapeutics, Cyclacel Pharmaceuticals Inc, DiscoveryBiomed Inc, Editas Medicine Inc, Eloxx ...
... Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that the U.S. Food and Drug Administration (FDA) ...
... GmbH, Catabasis Pharmaceuticals Inc, Celtaxsys Inc, Chiesi Farmaceutici SpA, Cilian AG, Concert Pharmaceuticals Inc, CRISPR Therapeutics, Cyclacel Pharmaceuticals Inc, DiscoveryBiomed Inc, Editas Medicine Inc, Eloxx ...
... has agreed to provide $30 million in venture debt financing to Concert Pharmaceuticals Inc. Based in Lexington, Massachusetts, Concert Pharmaceuticals is a clinical-stage biopharmaceutical company. ...
... Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has entered into a$30.0 millionventure debt ...
... Cara Therapeutics Inc. (NASDAQ: CARA), Cerus Corp. (NASDAQ: CERS), and Concert Pharmaceuticals Inc. (NASDAQ: CNCE). Learn more about these stocks by downloading their comprehensive and ...
... Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that Ryan Daws, Chief Financial Officer, will be ...
... Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at ...
Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!
Start My Free Trial ➤